Skip to content
yes i take peptides · shopping companion

SS-31 (Elamipretide)

Forzinity / SS-31
Category · For LongStatus · FDACitations · 60
The verdict

Yes for trial-eligible mitochondrial disease patients — no for healthy-adult longevity use.

By source — cost, legality, risk
  • Brand — Forzinity (Stealth Biotherapeutics)
    ~$200,000+/year via specialty pharmacy
    FDA-approved Sept 2025 · Barth syndrome only
    Lowest molecular. Ultra-rare-disease pricing; only realistic for diagnosed Barth patients with insurance coverage.
  • Compounded 503A pharmacy
    Not meaningfully available
    Not available — no 503A path post-approval
    Post-approval, 503A compounding is closed; brand or RUO are the only realistic channels.
  • RUO research peptide
    $80–$300/mo at community 1–4mg/d
    Sold 'for research only'
    Highest. The D-amino acid stereochemistry matters for activity; RUO product made with all-L is a different molecule. Chiral HPLC rarely run.
  • Gray-market raw
    $25–$125/mo
    Unregulated overseas import
    Crypto/Wise pay; same D-stereochemistry concern as RUO; identity verification by mass spec alone is insufficient.
Stop signals · abort if
  • persistent severe injection-site reaction
  • any new cardiac symptom (in cardiomyopathy population)
  • allergic reaction
  • any new mass or unexplained pain
Sources · top 5 of 60
  1. 01Zhao W, et al. Elamipretide (SS-31) improves mitochondrial dysfunction, synaptic and memory impairment induced by lipopolysaccharide in mice. Journal of neuroinflammation. 2019;16(1):230. PMID: 31747905.
  2. 02Zheng H, et al. SS-31@Fer-1 Alleviates ferroptosis in hypoxia/reoxygenation cardiomyocytes via mitochondrial targeting. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie. 2025;183:117832. PMID: 39848110.
  3. 03Nie Y, et al. Elamipretide(SS-31) Attenuates Idiopathic Pulmonary Fibrosis by Inhibiting the Nrf2-Dependent NLRP3 Inflammasome in Macrophages. Antioxidants (Basel, Switzerland). 2023;12(12). PMID: 38136142.
  4. 04Whitson JA, et al. Elamipretide (SS-31) treatment attenuates age-associated post-translational modifications of heart proteins. GeroScience. 2021;43(5):2395-2412. PMID: 34480713.
  5. 05Tung C, et al. Elamipretide: A Review of Its Structure, Mechanism of Action, and Therapeutic Potential. International journal of molecular sciences. 2025;26(3). PMID: 39940712.
⚠ Not medical advice

We are not your doctor. Consult a licensed clinician before injecting any peptide. Verify every dose, vial size, and unit count against your vendor’s Certificate of Analysis before drawing.

Printed Jun 15, 2026 · yesitakepeptides.com/peptides/ss-31